AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study
Autor: | Ibrahima Sanogo, Kouassi Gustave Koffi, Fabien Despas, ZH Adeba, Christophe Laurent, D. A. Silue, S Koui, RP Botty, K. Boidy, G. Compaci, A.S Bognini, Guy Laurent, Ismael Kamara |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male Cancer Research Pediatrics medicine.medical_specialty Adolescent Lymphoma medicine.medical_treatment CHOP lcsh:RC254-282 Health Services Accessibility Young Adult 03 medical and health sciences 0302 clinical medicine Surgical oncology Antineoplastic Combined Chemotherapy Protocols Health care Genetics medicine Humans Patient Navigation Prospective Studies 030212 general & internal medicine Healthcare Disparities Child Poverty Aged Chemotherapy business.industry Malignant lymphoma Cancer Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Survival Rate Cote d'Ivoire Oncology ABVD 030220 oncology & carcinogenesis Ambulatory Abandonment (emotional) Female business AMAFRICA program Research Article medicine.drug |
Zdroj: | BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019) BMC Cancer |
ISSN: | 1471-2407 |
DOI: | 10.1186/s12885-019-6478-3 |
Popis: | Background Previous studies have indicated that accompanying socially underserved cancer patients through Patient Navigator (PN) or PN-derived procedures improves therapy management and reassurance. At the Cancer Institute of Toulouse-Oncopole (France), we have implemented AMA (Ambulatory Medical Assistance), a PN-based procedure adapted for malignant lymphoma (ML) patients under therapy. We found that AMA improves adherence to chemotherapy and safety. In low-middle income countries (LMIC), refusal and abandonment were documented as major adverse factors for cancer therapy. We reasoned that AMA could improve clinical management of ML patients in LMIC. Methods This study was set up in the Abidjan University Medical Center (Ivory Coast) in collaboration with Toulouse. One hundred African patients were randomly assigned to either an AMA or control group. Main criteria of judgment were refusal and abandonment of CHOP or ABVD chemotherapy. Results We found that AMA was feasible and had significant impact on refusal and abandonment. However, only one third of patients completed their therapy in both groups. No differences were noted in terms of complete response rate (CR) (16% based on intent-to-treat) and median overall survival (OS) (6 months). The main reason for refusal and abandonment was limitation of financial resources. Conclusion Altogether, this study showed that PN may reduce refusal and abandonment of treatment. However, due to insufficient health care coverage, its ultimate impact on OS remains limited. |
Databáze: | OpenAIRE |
Externí odkaz: |